Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 2996-3001

  Peters, Lester J ^a   O'Sullivan, Brian ^a   Giralt, Jordi ^a   Fitzgerald, Thomas J ^a   Trotti, Andy ^a   Bernier, Jacques ^a   Bourhis, Jean ^a   Yuen, Kally ^a   Fisher, Richard ^a   Rischin, Danny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; TRIAZINE DERIVATIVE;

ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; CLINICAL TRIAL; FOLLOW UP; HEAD AND NECK TUMOR; INTERNATIONAL COOPERATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEAD AND NECK NEOPLASMS; HUMANS; INTERNATIONAL AGENCIES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY ASSURANCE, HEALTH CARE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZINES;

EID: 77954600968     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.4498     Document Type: Article

References (10)

1. Steel GG: The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol 11:31-53, 1988
2. Rischin D, Peters L, O'Sullivan B, et al: Tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
3. Khalil AA, Bentzen SM, Bernier J, et al: Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys 55:568-575, 2003 (Pubitemid 36169997)
4. Budach V, Zurlo A, Horiot JC: EORTC Radiotherapy Group: Achievements and future prospects - European Organisation for Research and Treatment of Cancer. Eur J Cancer 38:134-137, 2002 (suppl 4)
5. Martin LA, Krall JM, Curran WJ, et al: Influence of a sampling review process for radiation oncology quality assurance in cooperative group clinical trials: Results of the Radiation Therapy Oncology Group (RTOG) analysis. Radiother Oncol 36:9-14, 1995
6. Purdy JA, Harms WB, Michalski J, et al: Initial experience with quality assurance of multi-institutional 3D radiotherapy clinical trials: A brief report. Strahlenther Onkol 174:40-42, 1998 (suppl 2) (Pubitemid 28475982)
7. Hamilton C, Poulsen M, Walker Q, et al: Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01): Trans-Tasman Radiation Oncology Group. Australas Radiol 43:227-232, 1999 (Pubitemid 29260088)
8. Eisbruch A, Harris J, Garden AS, et al: Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys [epub ahead of print on June 17, 2009]
9. Fabian CJ, Mansfield CM, Dahlberg S, et al: Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group randomized study. Ann Intern Med 120:903-912, 1994 (Pubitemid 24179152)
10. Molineu A, Followill DS, Balter PA, et al: Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 63:577-583, 2005 (Pubitemid 41317176)